Pathophysiology Department, Athens University Medical School, 75 Mikras Asias str. 11527, Athens, [corrected] Greece.
Anticancer Res. 2013 Mar;33(3):1209-14.
Metastatic gastric adenocarcinoma confers a dismal prognosis. Several prognostic factors are needed to distinguish patients that will benefit from chemotherapy. In this setting, the prognostic impact of DNA ploidy is still unclear.
The records of 61 patients with metastatic gastric adenocarcinoma were retrospectively reviewed. Response to chemotherapy and overall survival (OS) were assessed and correlated to tumour DNA ploidy index, which was calculated by cytometric image analysis.
The median value of DNA ploidy index was 2.3. Patients with a low index responded better to chemotherapy than those with a higher index (p<0.01). Nevertheless, when the median value was used as a cut-off, no significant correlation of DNA ploidy index with response to chemotherapy (p=0.41) or OS (p=0.09) was observed.
The prognostic role of DNA ploidy in metastatic gastric adenocarcinoma is still debatable. In this study, a low DNA ploidy index was associated with favorable prognosis; however, a suitable cut-off value is not yet available.
转移性胃腺癌预后不良。需要一些预后因素来区分可能从化疗中获益的患者。在这种情况下，DNA 倍体的预后影响尚不清楚。
回顾性分析了 61 例转移性胃腺癌患者的记录。评估了化疗的反应和总生存期（OS），并将其与通过细胞计量图像分析计算的肿瘤 DNA 倍体指数相关联。
DNA 倍体指数的中位数为 2.3。低指数患者对化疗的反应优于高指数患者（p<0.01）。然而，当中位数用作截止值时，未观察到 DNA 倍体指数与化疗反应（p=0.41）或 OS（p=0.09）之间存在显著相关性。
DNA 倍体在转移性胃腺癌中的预后作用仍存在争议。在这项研究中，低 DNA 倍体指数与较好的预后相关；然而，目前还没有合适的截止值。
